Treatment of Anemia with Unani medicine Itrifal Fauladi

Clinical Validation of Unani Pharmacopoeal formulation Itrifal Fauladi in Su ul Qiniya (Anemia)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/08/015452

Enrollment

240

Registered

2018-08-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified Health Condition 2: null- Su ul Qiniya (Anemia)

Interventions

Intervention1: Itrifal Fauladi: 7 gm twice daily To be taken with water after meals for 6 weeks Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of any sex in the age group 18-65 years 2. Patients having SÅ«â?? al-Qinya (Anaemia) with Haemoglobin level 8-12 g/dL in men and 8-11 g/dL in women with or without any of the following signs and symptoms: ShuhÅ«b (Pallor) NaqÄ?hat (Weakness) Iâ??yÄ?â?? (Fatigue) â??Usr al-Tanaffus (Dyspnoea)

Exclusion criteria

Exclusion criteria: 1. Patients with severe anaemia (Hb 2. Patients having anaemia with any associated severe complications 3. Patients having occult blood positive on stool examination. 4. Patients with sickle cell anaemia, aplastic anaemia, sideroblastic anaemia, anaemia due to malignancies, thalassaemia, hereditary spherocytosis, and lead poisoning. 5. Patients with chronic diseases requiring long-term treatment such as diabetes mellitus, tuberculosis, HIV infection, leukaemia, endocrine disorders, haemorrhagic diathesis (hemophilia, ITP), bleeding piles, menorrhagia, metrorrhagia or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking study drug or could interfere with the interpretation of data. 6. Patients with concurrent serious hepatic, cardiac, renal or pulmonary dysfunction. 7. Pregnant and lactating women 8. H/o addiction (alcohol, drugs) 9. H/o Hypersensitivity to the study drug or any of its ingredients.

Design outcomes

Primary

Measure	Time frame
improvement in the sign and symptoms of Su ul Qiniya (AnemiaTimepoint: 6 weeks	—

Secondary

Measure	Time frame
Hematological and biochemical assessments for safetyTimepoint: 6 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026